Filtered By:
Drug: Xolair
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 1700 results found since Jan 2013.
Do regional geography and race influence management of chronic spontaneous urticaria?
Chronic spontaneous urticaria is defined as migratory evanescent pruritic blanching wheals that occur with variable frequency for 6 weeks or more, with or without accompanying angioedema. This condition affects approximately 0.1% to 1.4% of persons worldwide. Second-generation H1 antihistamines are the mainstay of management, with refractory cases often managed with an array of options, including H2 antihistamines, leukotriene receptor antagonists, glucocorticosteroids, immunosuppressive agents, and omalizumab.
Source: Journal of Allergy and Clinical Immunology - December 1, 2022 Category: Allergy & Immunology Authors: Giselle S. Mosnaim, Matthew Greenhawt, Polina Imas, Loretta Au, Stephanie Mehlis, John Oppenheimer, David Lang, Jonathan Bernstein, Marcus Shaker Tags: Review article Source Type: research
Monoclonal Antibodies (Biologics) for Allergic Rhinitis, Asthma, and Atopic Dermatitis During Pregnancy and Lactation
Asthma, allergic rhinitis, chronic urticaria, and atopic dermatitis are common diseases that affect hundreds of thousands of pregnant women each year. The authors discuss the use of biologics in women who are pregnant or lactating, indications, available safety information, and knowledge gaps. There are pregnant patients for which standard treatment is either inadequate or contraindicated; in those cases, monoclonal antibodies (biologics) should be considered despite the unknown risk to the fetus. In severe asthma, omalizumab is the best studied with reassuring available safety data. Insufficient safety data exist on mepol...
Source: Immunology and Allergy Clinics of North America - November 19, 2022 Category: Allergy & Immunology Authors: Courtney L. Ramos, Jennifer Namazy Source Type: research
Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients
Conclusion
This is the first large-scale study describing omalizumab real-life exposure patterns in adult and paediatric asthma patients in France with >10 years of follow-up. We showed the long-term maintenance of low HCRU in adults and children who discontinued omalizumab while asthma was controlled, notably for OCS use and hospitalisations for asthma.
Source: European Respiratory Journal - November 10, 2022 Category: Respiratory Medicine Authors: Humbert, M., Bourdin, A., Taille, C., Kamar, D., Thonnelier, C., Lajoinie, A., Rigault, A., Deschildre, A., Molimard, M. Tags: Asthma and allergy Original Articles: Asthma Source Type: research
Highlights in Asthma Therapy From CHEST 2022 Highlights in Asthma Therapy From CHEST 2022
From CHEST 2022, Dr Navitha Ramesh reports key data on biologic therapies for asthma patients, including results from the CLEAR study and trials on omalizumab, benralizumab, and tezepelumab.Medscape
Source: Medscape Allergy Headlines - November 9, 2022 Category: Allergy & Immunology Tags: Pulmonary Medicine ReCAP Source Type: news
Asthma and Anaphylaxis —interconnected entities
AbstractPurpose of reviewThe relationship between asthma and anaphylaxis is not completely defined, and it is necessary to establish their association and find out the influence of factors contributing to their development. Our aim is to review the most recent literature to optimize the diagnostic and therapeutic approach to both entities.Recent findingsIn severe asthma and anaphylaxis, we found a potentially fatal risk. Both diseases can coexist and, although their association is not entirely clear, poor asthma control seems to worsen the prognosis of anaphylaxis.SummaryKnowing the risk factors for the severity of an asth...
Source: Current Treatment Options in Allergy - November 7, 2022 Category: Allergy & Immunology Source Type: research
Omalizumab and allergen immunotherapy for respiratory allergies: A mini-review from the Allergen-Immunotherapy Committee of the Italian Society of Pediatric Allergy and Immunology (SIAIP)
Allergol Immunopathol (Madr). 2022 Nov 1;50(6):47-52. doi: 10.15586/aei.v50i6.495. eCollection 2022.ABSTRACTAlthough currently approved to treat severe asthma and chronic spontaneous urticaria, omalizumab has also been an effective and safe add-on treatment for other allergic diseases. Namely, omalizumab has been proposed to be used as add-on therapy in patients with allergic rhinitis and asthma and undergoing specific allergen immunotherapy (AIT). AIT is the only treatment that modifies the natural history of IgE-mediated diseases. This brief review summarizes the available evidence and controversies on the efficacy and s...
Source: Allergologia et Immunopathologia - November 6, 2022 Category: Allergy & Immunology Authors: Maria De Filippo Martina Votto Lucia Caminiti Francesco Carella Giovanna De Castro Massimo Landi Roberta Olcese Ilenia Panasiti Mario Vernich Salvatore Barberi Giorgio Ciprandi Gian Luigi Marseglia Source Type: research
